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RAPID COMMUNICATION
Endothelin receptor antagonism is protective in in vivo acute
cyclosporine toxicity
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Endothelin receptor antagonism is protective in in vivo acute cyclospo.
rifle toxicity. Endothelin (Et) has been implicated in cyclosporine A
(CsA) nephrotoxicity. We have previously shown that CsA treatment in
rats results in up-regulation of Et receptors specifically within the
kidney. The role of Et in vivo CsA nephrotoxicity was therefore studied
further with a new competitive antagonist, BQ- 123, specific for EtA
receptors (EtRA). Systemic administration of CsA in Munich-Wistar
rats resulted in marked glomerular hypoperfusion and hypoliltration,
with RPF in left and right kidneys falling by some 40% to 1.60 0.25
and 1.73 0.38mI/mm and GFR decreasing by some 20% to 0.61 0.05
and 0.67 0.11 mI/mm, respectively. Selective infusion of EtRA into
the left renal artery following systemic CsA treatment had no effect on
this hemodynamic pattern (RPF 1.58 0.29 and 1.92 0.34mI/mm and
GFR 0.60 0.09 and 0.70 0.08 mI/mm in left and right kidneys,
respectively, P = NS vs. CsA period). By contrast, intrarenal infusion
of EtRA prior to systemic administration of CsA resulted in a strikingly
different pattern of renal hemodynamics. Thus, EtRA pretreatment in
the left kidney protected against glomerular dysfunction following CsA:
RPF was maintained, 3.23 0.28 mI/mm versus 2.96 0.31 (P = NS
EtRA vs. EtRA + CsA), as was the GFR, 1.04 0.16 mI/mm versus
1.12 0.09 (P =NS). However, the contralateral right kidneys of these
rats, not pretreated with EtRA, showed no protective effect: RPF
decreased from 3.15 0.34 mI/mm to 2.39 0.19 and GFR from 1.04
0.10 mI/mm to 0.85 0.07 (P < 0.05). Infusion of saline instead of
EtRA was without protective effect, and EtRA itself did not alter
systemic or renal hemodynamics. Systemic EtRA in a dose comparable
to the intrarenal infusion given before CsA treatment was not protec-
tive: RPF fell from 3.36 0.23 mI/mm to 1.96 0.33 (P < 0.005), and
GFR decreased from 0.94 0.06 mI/mm to 0.67 0.12 (P < 0.05).
These studies support that local Et activation is pivotal in acute CsA
nephrotoxicity. Local pretreatment with a specific EtA antagonist can
largely prevent this CsA-induced glomerular hypofiltration and hypo-
perfusion.
Some degree of renal dysfunction is a predictable conse-
quence of treatment with cyclosporine A (CsA) [1, 2], and
vasoconstrjctjon of the renal microvasculature is a prominent
feature of this nephrotoxicity. Endothelin (Et) is believed to be,
at least in part, responsible for some of the renal dysfunction
[3—8]. Endothelin, the most powerful vasoconstrictor known,
exists as three isopeptides [9]. Although Et is widely distributed
throughout various organs, the kidney is particularly suscepti-
ble to Et's actions [5]. Several renal cell types, including
endothelial, mesangial as well as tubular epithelial cells, are
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capable of constitutive and stimulus-induced elaboration of Et
[5]. Endothelin effects vasoconstriction via specific receptors
having varying density and binding characteristics [10—12]. So
far, EtA, which binds specifically to Et-l, and EtB, which binds
all three isoforms, have been identified. Both EtA and Et8
receptors are found within the kidney [11—13].
The recent development of a specific antagonist of endothe-
lin's actions, endothelin receptor A antagonist (EtRA), has
allowed further study in this area. Recently we examined
myosin light chain phosphorylation, a biochemical marker of
contraction in mesangial cells which are widely held to be
important to the modulation of glomerular vascular tone. Ex-
posure of the cultured cells to Et itself or to CsA, caused a
significant and persistent increase in this parameter of mesan-
gial cell contraction. Pretreatment with EtRA substantially
ameliorated the in vitro contraction in response to Et itself and
in a setting likely involving Et, that is, CsA toxicity [14]. In the
current studies, we examined the in vivo effects of EtRA
administered either systemically or directly into the kidney in
acute cyclosporine nephrotoxicity, using the specific antagonist
to the EtA receptor, BQ-123 (Banyu Pharmaceutical Co., To-
kyo, Japan).
Methods
Experiments were done in male Munich-Wistar rats weighing
=200 to 300 g. The animals had access to standard rat chow and
tap water until the day of the experiment. Tracheotomy was
performed under mactin anesthesia (70 mg/kg body weight i.p.,
Konstanz, Germany), and indwelling polyethylene catheters
were inserted into femoral artery and vein and jugular vein for
blood sampling, monitoring of systemic blood pressure by an
electronic transducer (model p2306, Gould Inc., Cleveland,
Ohio, USA, connected to a recorder, Gould 2200S), and infu-
sion of inulin, p-aminohippuric acid and plasma to maintain
euvolemia [31.
Group 1 (N 6). Systemic cyclosporin A (CsA) followed by
left renal artery endothelin receptor antagonist (EtRA). In
addition to the above surgical preparation, the left renal artery
was gently isolated as previously described [3, 15]. Care was
taken not to disrupt the renal nerves and lymphatics. A sharp-
ened micropipette was inserted through the wall of the previ-
ously isolated wall of the left renal artery and infused with
saline. We have previously demonstrated that saline infusion of
the renal artery in this fashion does not cause hemodynamic
changes either systemically or in the renal microcirculation [3,
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15]. Baseline measurements of clearances of p-aminohippuric
acid and inulin to determine the renal plasma flow (RPF) and
glomerular filtration rate (GFR) were obtained. These were
followed by systemic administration of CsA (20 mg/kg body
weight i.v., given over 10 mm) and the clearances were re-
peated 60 minutes later, We have previously shown that this
dose decreases RPF and GFR [3, 4]. Following this, endothelin
receptor antagonist (EtRA) was infused through the left renal
artery micropipette in a dose of 0.76 mg/hr in a volume of 0.76
ml/hr, and continued throughout the experimental period.
EtRA, BQ-123, is a newly synthesized compound that is a
selective competitive antagonist of EtA receptors, and was the
gift from the Banyu Pharmaceutical Co. (Tokyo, Japan). It is
derived from modification by amino acid substitution of a
natural cyclic pentapeptide antagonist of EtA [16, 17] (a cyclo-
D-trp-D-asp-pro-D-val-leu-), obtained from Streptomyces mis-
akiensis and has a molecular wt of 611 [16, 17]. It has previously
been shown that EtRA at 1, 5 and 10 mg/kg body weight given
systemically antagonizes the increase in mean arterial blood
pressure induced by exogenous Et-1 (1 nmol/kg body weight
i.v.) [16]. Clearances were repeated in both infused and non-
infused kidneys some 45 to 60 minutes and 90 to 120 minutes
following initiation of EtRA infusion (N = 4; Fig. 2).
Group 2 (N = 6). Left renal artery EIRA followed by systemic
CsA. These rats were prepared identically to Group 1 except
that EtRA was infused first, and clearances from the infused left
kidney and contralateral non-treated kidney were obtained at
one hour. The EtRA was continued and CsA was administered
by systemic i.v. infusion over 10 minutes as in Group 1, and
clearances were repeated at one hour after CsA. An additional
two rats were identically prepared except that saline and not
EtRA was infused into the left renal artery.
Group 3 (N = 6). Systemic EtRA followed by systemic CsA.
Rats were prepared as the above groups except that no pipette
was inserted into the left main renal artery. Instead, EtRA was
administered systemically via the femoral vein at 5 mg/hr. This
dose was derived from previous in vivo experiments [16] and
the proportion of cardiac output perfusing one kidney (—15%).
While the EtRA was continued, CsA was administered and
clearances repeated.
Statistics
Values are expressed as mean I SE. Differences between
periods and between left and right kidneys were compared by
paired Student's t-test. Differences were considered statisti-
cally significant at P < 0.05.
Results
Group 1. Systemic cyclosporin A (CsA)followed by left renal
artery endothelin receptor antagonist (EtRA). Systemic blood
pressure (SBP) was 93 3 mm Hg at baseline. As previously
noted by us and others [3,4, 18], infusion of CsA increased SBP
in every animal, so that by 10 to 15 minutes SBP was on average
some 30 mm Hg higher than baseline. This acute hypertensive
effect following CsA is transient; one hour after CsA, SBP
returned towards baseline (99 4 mm Hg, P = NS vs.
baseline). One hour into the EtRA infusion SBP was virtually
identical to baseline (94 3 mm Hg, P = NS vs. baseline).
Hematocrit was 45 1% at baseline, 44 2 after CsA, and
slightly decreased to 42 2 after EtRA. Urine flow rates at
Rht GFR
- -
Baseline CsA i.v. EtRA
left renal artery
Fig. 1. Changes of RPF and GFR from baseline in rats given systemic
CsA followed by left renal artery infusion of EtRA. CsA caused
significant hypoperfusion/hypofiltration of both kidneys. Infusion of
EtRA into the left renal artery did not ameliorate this dysfunction in
either EtRA-infused (left) or non-infused (right) kidneys.
baseline, after CsA and during left intrarenal EtRA infusion
were on the left 0.0206 0.0040 mI/mm, 0.0178 0.0042 and
0.0222 0.0025, and on the right 0.0159 0.0045 ml/min,
0.0127 0.0036 and 0.0169 0.0033. Baseline RPF was 2.74
0.29 mI/mm in the left kidney and 3.06 0.27 in the right kidney
(Fig. 1). Systemic CsA caused a significant decrease in RPF to
1.60 0.25 mI/mm and 1.73 0.38 in left and right kidneys,
respectively (P < 0.005 vs. baseline in the left and right
kidneys). Infusion of EtRA into the left kidney following
systemic administration was without effect: RPF remained
virtually identical (1.58 0,29 mi/mm, P = NS vs. CsA), nor
was there an effect in RPF in the right kidney (1.92 0.34
mi/mm, P = NS vs. CsA). A similar pattern was seen for GFR.
Baseline GFR value in the left kidney was 0.77 0.06 mi/mm
and 0.86 0.04 in the right. Systemic infusion of CsA resulted
in uniform decrease in GFR in both left (0.61 0.05 ml/min, P
< 0.025) and right (0.67 0.11 mllmin, P < 0.05) kidneys.
Similar to RPF, left renal artery infusion of EtRA was without
effect on GFR in that kidney after 60 minutes of infusion (GFR
0.60 0.09 mI/mm, P = NS vs. CsA period) or after longer
infusion at 90 to 120 minutes (GFR 0.63 ml/min, P = NS).
Hypofiltration also persisted in the right kidney (GFR 0.70
0.08, P NS vs. CsA period). EtRA per se did not alter
systemic or local hemodynamics from baseline values.
Group 2. Left renal artery EtRA followed by systemic CsA.
Systemic parameters were not significantly altered by intrarenal
infusion of EtRA and systemic CsA: SBP was 103 4 mm Hg
during EtRA and 108 6 mm Hg one hour after systemic CsA
(P = NS). The transient hypertension following CsA was not
affected by intrarenal EtRA. Hematocrit was virtually un-
changed throughout the experimental periods, 45 2% and 45
1. Urine flow rates in the left EtRA-infused kidney were
higher than in the right: 0.0098 0.0020 mllmin versus 0.0056
0.0009 (P < 0.025). Following CsA, there was an increase only
in the left kidney, 0.0 142 0.0021 mI/mm versus 0.0081
0.0022 in the right. Compared with Group 1, infusion of EtRA
into the left renal artery caused a strikingly different hemody-
namic response to subsequent exposure to CsA (Fig. 2). Thus,
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Fig. 2. RPF and GFR in rats undergoing left
renal artery infusion of EtRA before systemic
CsA. The right kidney, not exposed to EtRA,
showed a fall in RPF and GFR in response to
CsA. In contrast, the left kidney, infused with
EtRA, maintained normal filtration after
systemic CsA.
in contrast to Group 1, where CsA caused a marked fall in RPF,
EtRA pretreatment of the left kidney maintained the values of
RPF following CsA: 3.23 0.28 mi/mm versus 2.96 0.31 (P =
NS). Similarly, there was no decrease in the value for GFR in
these EtRA pretreated kidneys subsequently exposed to CsA:
1.04 0.16 ml/min versus 1.12 0.09 (P = NS). By contrast,
in the contralateral right kidney not pretreated with EtRA, there
was a fall in RPF in all but one animal, on average from 3.15
0.34 mllmin to 2.39 0.19 (0.05 <P <0.1 vs. baseline). The
GFR in these non-EtRA treated right kidneys fell significantly
following CsA: from 1.04 0.10 mi/mm to 0.85 0.07 (P <0.05
vs. baseline). Of note, infusion of saline before CsA instead of
EtRA into the left main renal artery was without a protective
effect. Both the RPF and GFR fell in both the saline-infused and
contralateral kidneys (3.38 0.92 mI/mm vs. 2.85 0.92 and
4.48 0.18 vs. 3.33 0.95 for RPF in left and right kidneys,
respectively). Similarly, GFR was 1.01 0.24 mI/mm versus
0.70 0.28 and 1.18 0.10 versus 0.90 0.23 after saline and
CsA, in left and right kidneys, respectively.
Group 3. Systemic EtRA followed by systemic CsA. To assess
whether systemic (vs. direct intrarenal) pretreatment with
EtRA is protective in CsA-induced glomerular hypoperfusion
and hypofiltration, we studied another group of rats. EtRA was
administered through the femoral vein in a dose some seven-
fold larger than that given in left renal artery infusion. SBP
during EtRA infusion was 106 4 mm Hg. This systemic EtRA
infusion was without effect on the transient hypertension oc-
curring 10 to 15 minutes after CsA infusion. One hour after
CsA, SBP was unchanged (105 3 mm Hg, P = NS).
Hematocrit was identical throughout the experimental periods,
48 1%, Urine flow rate was 0.0052 0.0004 mI/mm after
EtRA and 0.0057 0.0012 after CsA (P = NS). RPF was 3.36
0.23 mI/mm (N = 6) and fell to a similar degree as in Group
1 CsA-treated rats, to 1.96 0.33 ml/min (N 5, P < 0.005;
Fig. 3). Similarly, GFR of 0.94 0.06 ml/min during systemic
EtRA treatment dropped dramatically to 0.67 0.12 ml/min
following CsA administration (P <0.05).
Discussion
Cyclosporine results in a wide spectrum of cellular injury,
ranging from subtle changes in endothelial cells to thrombotic
microangiopathy [1, 21. Functional studies support the promi-
nence of vascular injury and vasoconstriction in all forms of
cyclosporine nephrotoxicity, from the acute to the more
chronic forms. Our previous studies documented that CsA can
promptly increase circulating Et-1 but that the increase is
transient, while renal vasoconstriction is prolonged [3, 4].
Further, we and others showed that the glomerular dysfunction
can be lessened by treatment with an antibody directed against
Et, supporting a role for Et in this pathophysiologic setting [3,
71. Although the circulating Et and glomerular dysfunction
dissociated, companion studies revealed that CsA causes up-
regulation of receptors for Et within the kidney. Up-regulation
of Et receptor was not seen in other tissue, notably the liver [4].
Additionally, the studies showed that not only was this up-
regulation particular to the kidney, it was specific for Et, as
another vasoconstrictor, that is, angiotensin II, did not show
increased binding in these CsA-treated animals [4]. Overall,
similar to studies in cardiac tissue, which show ischemia-
induced up-regulation of Et receptors [19], these studies sup-
port the potential for an important role for up-regulation of Et
receptors in pathophysiologic mechanisms of CsA-induced gb-
merular dysfunction.
Of interest in this regard are our recent in vitro studies using
the Et receptor antagonist. These experiments showed that
EtRA can lessen Et-induced increase in the biochemical para-
meter of mesangial cell contraction, that is, myosin light chain
phosphorylation. In addition, EtRA abrogated the increased
myosin light chain phosphorylation which followed mesangial
cell exposure to CsA, raising the intriguing possibility that
CsA-induced up-regulation in Et receptors can be modulated so
as to lessen vasoconstriction of glomerular microvasculature in
vivo. These issues, then, were explored in the current in vivo
experiments.
We again found that CsA causes hypoperfusion and hypofil-
tration [3, 4]. Administration of EtRA after CsA treatment
resulted in no improvement in the hypoperfusion/hypofiltration.
This observation points to rapid cellular changes known to
occur with cyclosporine, which cannot be reversed by EtRA.
Post-facto treatment with EtRA may have been ineffective
because CsA-evoked Et becomes tightly bound to its receptors.
Previous studies have shown that circulating levels of Et
increase rapidly after CsA exposure, thought to represent
"spillover" due to marked release of Et from injured renal cells
[5, 20, 21]. Thus, these levels may precede or exceed the
increased binding capacity due to the up-regulation of Et
receptors seen after CsA exposure, suggesting that shortly after
CsA exposure, all renal Et binding sites are saturated. It is not
surprising, therefore, that EtRA was not effective when given
after CsA. Conceivably, given at high enough doses to displace
Right
NoRx CsA
RPF: 3.15±0.34 2.39±0.19
GFR: 1.04±0.10 0.85*0.Ot
Left
EtRA CSA
RPF: 3.23±0.28 2.96±0.31
GFR;1.04±0.16 1.12±0.09
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In contrast to these experiments, when Et antagonist was
infused before cyclosporine treatment, the kidneys were re-
markably protected from glomerular hypofiltration (Fig. 2),
suggesting that pretreatment with EtRA may modulate receptor
susceptibility to subsequent CsA/Et activation. This is in good
agreement with studies by Lanese, Schrier and Conger who
showed that pretreatment with EtRA ameliorated CsA-induced
renal arteriolar vasoconstriction [22]. EtRA also was successful
in preventing renal parenchymal damage, both functional and
morphological, in the isolated perfused kidney made ischemic
[231. Since BQ-123 receptor antagonist has little effect on EtB
receptors, the protective effects apparent with EtRA pretreat-
ment suggest that EtA receptors, rather than EtB receptors, are
of primary importance. Of note, the possibility that EtB recep-
tors contribute to some extent to the vasoconstriction associ-
ated with CsA awaits development of specific antagonist to this
receptor.
Although intrarenal administration of EtRA prior to CsA
exposure prevented CsA-induced glomerular dysfunction, sys-
temic administration of equivalent doses of EtRA, as used in
intrarenal infusion, offered no protection against CsA-induced
glomerular damage. The equivalent dose for systemic infusion
was some sevenfold higher than the dose for local renal
infusion, and was based on the relative blood flow to one kidney
(15%) versus total cardiac output. However, this protocol was
not protective against CsA-induced glomerular hypofunction.
In this regard, the kidney contains both EtA and EtB receptors,
whereas systemic vasculatures are rich in EtA receptors [10—13,
Note added in proof]. The lung expresses high levels of both EtA
and EtB receptors, and may also affect activity of systemically
infused receptor Et antagonists. Thus, systemic treatment with
EtRA may have to be given at very high doses to overcome the
high systemic binding capacity for Et. The implication of these
results is that systemic EtA receptors are not of primary
importance in CsA-induced renal vasoconstriction. Rather,
since EtRA infused locally, but not systemically, was protec-
tive, it is local renal Et activation which is pivotal in this
vasoconstriction. This notion is also supported by our previous
study showing that increased Et receptors in response to CsA
were specific to the kidney [4]. In the two preliminary studies in
ex vivo models which show protective effect of Et receptor
antagonist, the renal vessels were also directly exposed to
EtRA [22, 23]. Thus, analogous to other disorders, such as
post-ischemia and endotoxemia [5], in CsA nephrotoxicity,
local Et activity rather than systemic actions are pivotal in
determining functional consequences.
Our studies support that CsA results in acute renal hypofil-
tration and hypoperfusion due to local changes in endothelin
physiology. Local changes within the kidney which include
increased density of EtA receptors appear to be primary mod-
ulators of renal vasoconstriction. An important implication of
these findings is that CsA-associated pathophysiologic changes
can be largely prevented by local pretreatment with a specific
EtA antagonist.
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endogenous Et bound to receptor sites, EtRA could improve
renal dysfunction following CsA.
These findings are also consistent with the known mechanism
of action of this antagonist [161. The EtRA BQ-123 is a
competitive antagonist highly specific against EtA, and there-
fore acts by binding unoccupied receptor sites. Thus, once CsA
initiates cellular events which potentially include up-regulation
of Et receptors as well as increased elaboration of Et, EtRA's
potential to reverse toxicity is diminished. It is also possible
that lack of amelioration when EtRA was given after CsA
indicates that EtB receptors, not affected by this specific EtA
antagonist, play a role in renal vasoconstriction in CsA-induced
nephroxicity.
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